← Zurück zum Screener

Edgewise Therapeutics

EWTX Mid Cap

Healthcare · Biotechnology

Aktualisiert: Apr 5, 2026, 17:43 UTC

$33.33
+0.57% heute
52W: $10.60 – $33.55
52W Low: $10.60 Position: 99% 52W High: $33.55

Kennzahlen

P/E Ratio
Kurs/Gewinn-Verhältnis
Forward P/E
Erwartetes KGV
P/S Ratio
Kurs/Umsatz-Verhältnis
EV/EBITDA
Unternehmenswert/EBITDA
Dividendenrendite
Jährl. Dividendenrendite
Market Cap
$3.6B
Marktkapitalisierung
Umsatzwachstum
YoY Umsatzwachstum
Gewinnmarge
Nettomarge
ROE
-34.19%
Eigenkapitalrendite
Beta
0.25
Marktsensitivität
Short Interest
10.34%
% der Aktien leerverkauft
Ø Volumen
975,018
Durchschn. Tagesvolumen

Bewertungs-Analyse

Signal
N/A
vs. S&P 500 Ø KGV (24.7x)
Analysten-Konsens
Kaufen
12 Analysten
Ø Kursziel
$41.08
+23.26% Upside
Kursziel Spanne
$20.00 – $51.00

Über das Unternehmen

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address ge

Sektor: Healthcare Branche: Biotechnology Land: United States Mitarbeiter: 146 Börse: NMS

Trading-Daten

50-Day MA: $29.83
200-Day MA: $20.72
Volumen: 971,022
Ø Volumen: 975,018
Short Ratio: 10.5
Kurs/Buchwert: 6.78x
Verschuldung/EK: 0.76x
Free Cash Flow: $-87,337,752

Wo kann ich Edgewise Therapeutics kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.

Nach oben scrollen